[Skip to Content]
[Skip to Content Landing]
Viewpoint
December 5, 2019

Survival in Oligometastatic Prostate Cancer—A New Dawn or the Will Rogers Phenomenon?

Author Affiliations
  • 1Imperial Prostate, Department of Surgery and Cancer, Faculty of Medicine, Charing Cross Hospital, Imperial College London, London, United Kingdom
  • 2Imperial College Healthcare Nationals Health Service Trust, Department of Urology, Charing Cross Hospital, London, United Kingdom
JAMA Oncol. 2020;6(2):185-186. doi:10.1001/jamaoncol.2019.4724

Oligometastatic prostate cancer refers to the cases affecting a group of patients with a potentially highly favorable limited metastatic state, defined exclusively by clinical features.1 The cases affecting this group challenge the long-held oncological paradigm that metastasis from solid-organ malignant conditions are not controllable and thus should be managed with palliative intent. In the wake of the US Preventive Services Task Force 2012 recommendation against routine prostate-specific antigen screening, de novo metastatic prostate cancer incidence has experienced a relative increase of 57.1% (from 4.9% to 7.7%; P = .08), equating to an expected 15 097 diagnoses per year by 2025.2 Nonetheless, overall survival in this group of patients has also dramatically increased with the use of early, novel systemic agents, such as docetaxel.3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×